Mira Pharmaceuticals (MIRA) Net Cash Flow (2022 - 2025)
Mira Pharmaceuticals (MIRA) posted Net Cash Flow of $3.7 million for Q4 2025, up 94.91% sequentially from $1.9 million in Q3 2025, and up 379.58% YoY from $764638.2 in Q4 2024.
Mira Pharmaceuticals (MIRA) Net Cash Flow (2022 - 2025) Analysis & Trends
Mira Pharmaceuticals (MIRA) has 4 years of Net Cash Flow data on file, last reported at $3.7 million in Q4 2025.
- Quarterly Net Cash Flow rose 379.58% year-over-year to $3.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.5 million (up 296.41% YoY) and the FY2025 annual result came in at $3.5 million, up 296.41% from the prior year.
- Net Cash Flow advanced to $3.7 million in Q4 2025 per MIRA's latest filing, from $1.9 million in the prior quarter.
- The five-year high for Net Cash Flow was $5.8 million in Q3 2023, with the low at -$1.6 million in Q1 2025.
- Average Net Cash Flow over 4 years is $391614.8, with a median of -$412894.0 recorded in 2023.
- Year-over-year, Net Cash Flow surged 1015.1% in 2023 and tumbled 3102.96% in 2024.
- Mira Pharmaceuticals' Net Cash Flow stood at $163563.0 in 2022, then sank by 873.87% to -$1.3 million in 2023, then retreated by 3.62% to -$1.3 million in 2024, then soared by 379.58% to $3.7 million in 2025.
- Business Quant data shows MIRA's Net Cash Flow at $3.7 million in Q4 2025, $1.9 million in Q3 2025, and -$476159.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | -2.05 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 2.00 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 4.17 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -1.53 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -9.27 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 2.91 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 75.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 544.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Mira Pharmaceuticals | 22.51 Mn | 11.48 Mn | - | 3.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.67 Mn |
| Dec 31, 2025 | 3.67 Mn |
| Sep 30, 2025 | 1.88 Mn |
| Sep 30, 2025 | 1.88 Mn |
| Jun 30, 2025 | -476,159.00 |
| Jun 30, 2025 | -476,159.00 |
| Mar 31, 2025 | -1.60 Mn |
| Mar 31, 2025 | -1.60 Mn |
| Dec 31, 2024 | -1.31 Mn |
| Dec 31, 2024 | -1.31 Mn |
| Sep 30, 2024 | 1.32 Mn |
| Sep 30, 2024 | 1.32 Mn |
| Jun 30, 2024 | -704,914.00 |
| Jun 30, 2024 | -704,914.00 |
| Mar 31, 2024 | -1.07 Mn |
| Mar 31, 2024 | -1.07 Mn |
| Dec 31, 2023 | -1.27 Mn |
| Dec 31, 2023 | -1.27 Mn |
| Sep 30, 2023 | 5.84 Mn |
| Sep 30, 2023 | 5.84 Mn |